{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:41Z","timestamp":1785186521335,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005441.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000}}],"reference-count":147,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005441.pub3","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T16:06:52Z","timestamp":1393603612000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C"],"prefix":"10.1002","volume":"2014","author":[{"given":"Goran","family":"Hauser","sequence":"first","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51 000"},{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Department 7812, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahany","family":"Awad","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Department 7812, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Brok","sequence":"additional","affiliation":[{"name":"Rigshospitalet; Paediatric Department 4072; Blemdagsvej 9 Copenhagen Denmark 2100 \u00d8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Thorlund","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Clinical Epidemiology and Biostatistics; Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"\u0160timac","sequence":"additional","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51 000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasen","family":"Mabrouk","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Cairo University; Endemic Medicine and Liver Department; Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Department 7812, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital Hvidovre; Gastro Unit, Medical Division; Kettegaards Alle Hvidovre Denmark 2650"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"key":"10.1002\/14651858.CD005441.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1478-3231.2004.0976.x","article-title":"Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4","volume":"24","author":"Alfaleh","year":"2004","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2004.05.012","article-title":"Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial","volume":"41","author":"Bruno","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005441.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0168-8278(03)80717-1","article-title":"Chronic hepatitis C (CH-C) genotype 1: an independent, multicenter RCT comparing PEG-IFN alfa-2b 12 kD plus ribavirin (RBV) and IFN alfa-2b plus RBV in naive patients","volume":"38","author":"Bruno","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0004|cit4","first-page":"595A","article-title":"PEG-INF alpha-2A (40KD) plus ribavirin (RBV) vs IFN alpha-2A (ROFERON-A) in naive patients with chronic hepatitis C (CHC) and genotype 1 [AASLD abstract]","volume":"36","author":"Cariti","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1365-2893.2005.00604.x","article-title":"Pegylated interferon-alpha 2b- ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis","volume":"12","author":"Derbala","year":"2005","journal-title":"Journal of Viral Hepatitis"},{"issue":"35","key":"10.1002\/14651858.CD005441.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.3748\/wjg.v12.i35.5692","article-title":"Treatment of hepatitis C virus genotype 4 with pegylated interferon alpha 2a:Impact of bilharziasis and fibrosis stage","volume":"12","author":"Derbala","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0007|cit7","first-page":"691","article-title":"Efficacy of daily consensus interferon and ribavirin compared to peg-interferon alpha-2B and interferon in non-responders with chronic hepatitis C [AASLD abstract]","volume":"42","author":"Dollinger","year":"2005","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"314A","DOI":"10.1016\/S0270-9139(03)80367-1","article-title":"Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin [AASLD abstract]","volume":"38","author":"Esmat","year":"2003","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"733A","DOI":"10.1016\/S0270-9139(03)81232-6","article-title":"End of treatment and sustained response to peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2a (Roferon-A) plus RBV and AMA in IFN\/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]","volume":"38","author":"Fargion","year":"2003","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005441.pub3-BIB0011|cit10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0168-8278(03)80745-6","article-title":"Peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN\/RBV nonresponder patients with chronic hepatitis C (CHC)","volume":"38","author":"Fargion","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0010|cit11","first-page":"572A","article-title":"Peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN\/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]","volume":"36","author":"Fargion","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0168-8278(04)90475-8","article-title":"Sustained virological response (SVR) to peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN\/RBV non responders (NR) with chronic hepatitis C (CHC)","volume":"40","author":"Fargion","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005441.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1665-2681(19)32139-8","article-title":"Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial","volume":"2","author":"Bosques-Padilla","year":"2003","journal-title":"Annals of Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD005441.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2003.12.014","article-title":"The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C","volume":"40","author":"Hassanein","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0016|cit16","first-page":"243A","article-title":"Treatment with 40 kDa peginterferon alfa-2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa-2b plus ribavirin [AASLD abstract]","volume":"34","author":"Hassanein","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0168-8278(02)80388-9","article-title":"QOL benefits observed as early as week 2 with peginterferon alfa-2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV [EASL abstract]","volume":"36","author":"Hassanein","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005441.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","article-title":"Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon","volume":"37","author":"Herrmann","year":"2003","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD005441.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/jhep.2003.50238","article-title":"Viral kinetics in hepatitis C","volume":"37","author":"Lutchman","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00019053-200422040-00004","article-title":"Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C","volume":"22","author":"Sullivan","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005441.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0168-8278(03)80867-X","article-title":"A comparison of cost-effectiveness of peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC)","volume":"38","author":"Sullivan","year":"2003","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/j.1572-0241.2004.30286.x","article-title":"Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C","volume":"99","author":"Sullivan","year":"2004","journal-title":"American Journal of Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0023|cit23","first-page":"558A","article-title":"Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]","volume":"34","author":"Zeuzem","year":"2001","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0024|cit24","first-page":"311A","article-title":"A prospective randomised 24 week trial of peg-interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]","volume":"36","author":"Hinrichsen","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005441.pub3-BIB0025|cit25","first-page":"293","article-title":"Weekly pegylated Interferon alpha-2b vs daily interferon a-2b versus standard regimen of Interferon a-2b in the treatment of patients with chronic hepatitis C virus infection","volume":"71","author":"Horsmans","year":"2008","journal-title":"Acto Gastro-Enterologica Belgica"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000077833","article-title":"A comparison of the exponential decay slope between PEG-IFN alfa-2b\/ribavirin and IFN alfa-2b\/ribavirin combination therapy in patients with chronic hepatitis C","volume":"47","author":"Izumi","year":"2004","journal-title":"Intervirology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2893.2005.00590.x","article-title":"Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan","volume":"12","author":"Lee","year":"2005","journal-title":"Journal of Viral Hepatitis"},{"issue":"3","key":"10.1002\/14651858.CD005441.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2893.2005.00591.x","article-title":"A randomized controlled trial of peginterferon alpha-2a (40 kD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C","volume":"12","author":"Mangia","year":"2005","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1365-2036.2003.01453.x","article-title":"A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C","volume":"17","author":"Buti","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0030|cit30","first-page":"141","article-title":"Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial","volume":"9","author":"Condat","year":"2002","journal-title":"Hepato-Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0031|cit31","first-page":"582A","article-title":"Treatment with pegylated interferon alfa-2b in combination with ribavirin improved health-related quality of life compared with interferon alfa-2b plus ribavirin in chronic hepatitis C [AASLD abstract]","volume":"36","author":"Gish","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mcp.2002.127112","article-title":"Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models","volume":"72","author":"Jen","year":"2002","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0033|cit33","first-page":"297A","article-title":"Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]","volume":"32","author":"Manns","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0168-8278(01)80007-6","article-title":"Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg-interferon alfa-2b plus ribavirin [abstract]","volume":"34","author":"McHutchison","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0037|cit37","first-page":"417A","article-title":"Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin","volume":"34","author":"McHutchison","year":"2001","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0038|cit38","first-page":"329A","article-title":"Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg\/kg of body weight? [AASLD abstract]","volume":"34","author":"McHutchison","year":"2001","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD005441.pub3-BIB0039|cit39","first-page":"351A","article-title":"Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated-interferon alpfa-2b and ribavirin combination [AASLD abstract]","volume":"36","author":"Poynard","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/jhep.2003.50319","article-title":"Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin","volume":"38","author":"Poynard","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/jhep.2003.50267","article-title":"Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C","volume":"38","author":"Poynard","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"Siebert","year":"2003","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD005441.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/j.1572-0241.2003.t01-1-08735.x","article-title":"Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C","volume":"98","author":"Wong","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0044|cit44","first-page":"13","article-title":"Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C","volume":"28","author":"Napoli","year":"2005","journal-title":"New Microbiologica"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0045|cit45","first-page":"223","article-title":"A randomised, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in na\u00efve and relapsed chronic hepatitis C patients","volume":"73","author":"Nevens","year":"2010","journal-title":"Acta Gastroenterologica Belgica"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0046|cit46","first-page":"200","article-title":"Enhanced response to peginterferon-alpha-2a-based triple therapy in previously non-responsive chronic hepatitis C: final results of PRETTY study","volume":"42","author":"Mangia","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0047|cit47","first-page":"826A","article-title":"Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotype 1","volume":"46","author":"Rahman","year":"2007","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0048|cit48","first-page":"826A","article-title":"Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 or 3","volume":"46","author":"Rahman","year":"2007","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0049|cit49","first-page":"322A","article-title":"Efficacy and safety of low doses of interferon (IFN) alfa-2b plus ribavirin (RBV) in advanced HCV related liver disease [AASLD abstract]","volume":"40","author":"Roffi","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005441.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/135965350801300506","article-title":"Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis","volume":"13","author":"Roffi","year":"2008","journal-title":"Antiviral Therapy"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0051|cit51","first-page":"23","article-title":"Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b\/ribavirin combined regimens in naive patients","volume":"28","author":"Scotto","year":"2005","journal-title":"New Microbiologica"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"636A","DOI":"10.1016\/S0270-9139(03)81034-0","article-title":"Combination therapy of peginterferon alfa-2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]","volume":"38","author":"Shobokshi","year":"2003","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(02)80462-7","article-title":"Efficacy of pegylated (40kDa) IFN alfa-2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia","volume":"36","author":"Shobokshi","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005441.pub3-BIB0054|cit54","first-page":"S92","article-title":"Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin","volume":"24","author":"Shobokshi","year":"2003","journal-title":"Saudi Medical Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005441.pub3-BIB0055|cit55","first-page":"S92","article-title":"Pegylated interferon alfa-2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients","volume":"24","author":"Shobokshi","year":"2003","journal-title":"Saudi Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD005441.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1007\/s10620-007-9757-9","article-title":"Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin","volume":"52","author":"Sjogren","year":"2007","journal-title":"Digestive Diseases and Sciences"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"278A","DOI":"10.1016\/S0270-9139(03)80295-1","article-title":"Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients [AASLD abstract]","volume":"38","author":"Thakeb","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.20232","article-title":"Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load","volume":"75","author":"Tsubota","year":"2005","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S1386-6532(06)80440-3","article-title":"Peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in treatment-naive Egyptian patients","volume":"36","author":"Wakil","year":"2006","journal-title":"Journal of Clinical Virology"},{"issue":"5","key":"10.1002\/14651858.CD005441.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2004.11.059","article-title":"Viral kinetics in hepatitis C or hepatitis C\/human immunodeficiency virus-infected patients","volume":"128","author":"Sherman","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0062|cit62","first-page":"127","article-title":"Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients","volume":"22","author":"Ali","year":"2010","journal-title":"Journal of\u00a0Ayub\u00a0Medical College"},{"issue":"13","key":"10.1002\/14651858.CD005441.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrhosis during interferon-based therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/379255","article-title":"Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV\/HIV coinfection","volume":"188","author":"Torriani","year":"2003","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005441.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0066|cit66","first-page":"338A","article-title":"Enhanced interferon (IFN)-stimulated gene expression and HCV dynamics in patients treated with pegylated IFN alfa 2b and ribavirin: effect of pharmacokinetic change of IFN and ribavirin","volume":"40","author":"Asahina","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0067|cit67","first-page":"31","article-title":"Comparative efficacy of combined treatment with Intron a and Pegintron in combination with ribavirin in patients with chronic hepatitis C","volume":"76","author":"Gromova","year":"2004","journal-title":"Terapevticheskii Arkhiv"},{"issue":"13","key":"10.1002\/14651858.CD005441.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"issue":"23","key":"10.1002\/14651858.CD005441.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005441.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0168-8278(04)90491-6","article-title":"Comparison of HCV RNA and HCV core antigen kinetics in the follow up of a therapeutic protocol in HCV-HIV co-infected patients (RIBAVIC)","volume":"40","author":"Lunel","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0071|cit71","first-page":"315A","article-title":"Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected [AASLD abstract]","volume":"40","author":"Pol","year":"2004","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005441.pub3-BIB0072|cit72","first-page":"10","article-title":"Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for naive HCV-HIV co-infected patients","volume":"42","author":"Pol","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep.23000","article-title":"Effect of hepatitis C virus and its treatment on survival","volume":"50","author":"Adeel","year":"2009","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD005441.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/hepr.12084","article-title":"Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: a systematic review and meta-analysis","volume":"43","author":"Aljumah","year":"2013","journal-title":"Hepatology Research"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/hep.23504.","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of interferon: a 40\u00a0kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconjugate Chemistry"},{"issue":"9654","key":"10.1002\/14651858.CD005441.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(08)61560-3","article-title":"Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis","volume":"372","author":"Bangalore","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0166-3542(01)00185-1","article-title":"Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus-related cirrhosis","volume":"52","author":"Benvegnu","year":"2001","journal-title":"Antiviral Research"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"8","key":"10.1002\/14651858.CD005441.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive\u2014trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005445.pub2","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0083|cit83","first-page":"346:e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"8","author":"Chan","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"S1","key":"10.1002\/14651858.CD005441.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hep.1840360718","article-title":"Treatment of chronic hepatitis C: a systematic review","volume":"36","author":"Chander","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0085|cit85","first-page":"105","article-title":"Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic\/hypomanic and depressive symptoms","volume":"66","author":"Constant","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0086|cit86","unstructured":"Copenhagen Trial Unit TSA\u2014Trial Sequential Analysis ctu.dk\/tsa\/"},{"issue":"6B","key":"10.1002\/14651858.CD005441.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0002-9343(99)00376-9","article-title":"Hepatitis C virus genotypes and quasispecies","volume":"107","author":"Davis","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005441.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods of combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005441.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s10620-010-1220-7","article-title":"Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C","volume":"55","author":"Dhillon","year":"2010","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD005441.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD005441.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2036.2004.02170.x","article-title":"Pegylated interferons: chemical and clinical differences","volume":"20","author":"Foster","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005441.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-[alpha]2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data","volume":"68","author":"Glue","year":"2000","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0097|cit97","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2013, Issue 12. Art. No.: LIVER"},{"issue":"12","key":"10.1002\/14651858.CD005441.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"e83313","DOI":"10.1371\/journal.pone.0083313","article-title":"Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?","volume":"8","author":"Gurusamy","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"346\u201355","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0101|cit101","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005642.pub3","article-title":"Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C (Review)","author":"Hauser","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD005441.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0103|cit103","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/hep.23002","article-title":"Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study","volume":"50","author":"Uto","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0105|cit105","article-title":"Viral hepatitis\u2014clinical aspects","volume-title":"Oxford Textbook of Medicine","author":"Hodgson","year":"2003"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0107|cit107","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"9","key":"10.1002\/14651858.CD005441.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2036.2004.02208.x","article-title":"Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4","volume":"20","author":"Khuroo","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD005441.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003617","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Koretz","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7497","key":"10.1002\/14651858.CD005441.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/bmj.330.7497.956","article-title":"Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement","volume":"330","author":"Krleza-Jeric","year":"2005","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1111\/j.1572-0241.2002.05999.x","article-title":"Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C","volume":"97","author":"Kumar","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000260228","article-title":"Pegylated-interferon-associated retinopathy in chronic hepatitis patients","volume":"224","author":"Lim","year":"2010","journal-title":"Ophtalmologica"},{"issue":"12","key":"10.1002\/14651858.CD005441.pub3-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"10","author":"Moher","year":"2012","journal-title":"International Journal of Surgery"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000370","article-title":"Interferon for interferon naive patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0118|cit118","unstructured":"United Network for Organ Sharing Chapter IV; Liver and Intestine Transplantation in the United States, 1998-2007 optn.transplant.hrsa.gov\/ar2008\/chapter_iv_AR_cd.htm?cp=5"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Penin F Dubuisson J Rey FA Moradpour D Pawlotsky J Structural biology of hepatitis C virus Hepatology 2004 5 19 10.1002\/hep.20032","DOI":"10.1002\/hep.20032"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-alpha: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD005441.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"433\u20138","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferonalpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C","volume":"33","author":"Reddy","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0122|cit122","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2010.04.013","article-title":"Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C","volume":"53","author":"Roomer","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1006\/jmbi.2001.5055","article-title":"Recent advances in the molecular biology of hepatitis C virus","volume":"313","author":"Rosenberg","year":"2001","journal-title":"Journal of Molecular Biology"},{"issue":"4","key":"10.1002\/14651858.CD005441.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/sim.2971","article-title":"Arcsine test for publication bias in meta-analyses with binary outcomes","volume":"27","author":"R\u00fccker","year":"2008","journal-title":"Statistics in Medicine"},{"issue":"35","key":"10.1002\/14651858.CD005441.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"16","author":"Savovic","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD005441.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovic","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD005441.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0130|cit130","doi-asserted-by":"crossref","unstructured":"Seeff LB Hoofnagle JH National institutes of health consensus development conference: management of hepatitis C: 2002 Hepatology 2002 S1 S2 10.1002\/hep.1840360702","DOI":"10.1053\/jhep.2002.36992"},{"issue":"S1","key":"10.1002\/14651858.CD005441.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1478-3231.2008.01927.x","article-title":"The history of the \"natural history\" of hepatitis C (1968-2009)","volume":"29","author":"Seeff","year":"2009","journal-title":"Liver International"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1017\/S0266462305050063","article-title":"Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation","volume":"21","author":"Shepherd","year":"2005","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S0266462305050075","article-title":"Effectiveness and cost-effectiveness of initial combination therapy with interferon\/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security","volume":"21","author":"Siebert","year":"2005","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10620-009-0797-1","article-title":"Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature","volume":"55","author":"Slavenburg","year":"2010","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0139|cit139","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0140|cit140","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual forTrial Sequential Analysis (TSA) ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0141|cit141","first-page":"599","article-title":"Virus Taxonomy: The Classification and Nomenclature of Viruses","volume-title":"The Seventh Report of the International Committee on Taxonomy of Viruses","author":"Regenmortel","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD005441.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","article-title":"Global surveillance and control of hepatitis C","volume":"6","author":"World Health Organization (WHO)","year":"1999","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0145|cit145","unstructured":"WHO International Clinical Trials Registry Platform (ICTRP) www.who.int\/ictrp\/en\/"},{"key":"10.1002\/14651858.CD005441.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7","key":"10.1002\/14651858.CD005441.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2036.2003.01747.x","article-title":"Peginterferon vs. standard interferon in the treatment of chronic hepatitis C","volume":"18","author":"Zaman","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD005441.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T03:58:10Z","timestamp":1714190290000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005441.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":147,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005441.pub3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718293980.793492011","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]}}}